European urology最新文献

{"title":"Re: Maarten De Rooij, Clare Allen, Jasper J. Twilt, et al. PI-QUAL Version 2: An Update of a Standardised Scoring System for the Assessment of Image Quality of Prostate MRI. Eur Radiol. In press. https://doi.org/10.1007/s00330-024-10795-4","authors":"Geert Villeirs, Valeria Panebianco, Caroline M. Moore, Jelle O. Barentsz","doi":"10.1016/j.eururo.2024.10.021","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.021","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"40 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Marc-Oliver Grimm, Mototsuga Oya, Toni K. Choueiri, et al. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Eur Urol 2024;85:8–12","authors":"Michael Froehner","doi":"10.1016/j.eururo.2024.02.027","DOIUrl":"10.1016/j.eururo.2024.02.027","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Page e126"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More Than Words: Defining Adjuvant, Consolidative, and Salvage Treatment after Radical Prostatectomy","authors":"Brian R. Lane , Robert T. Dess , Tudor Borza","doi":"10.1016/j.eururo.2024.02.024","DOIUrl":"10.1016/j.eururo.2024.02.024","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 385-387"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140308397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Association of Urology/European Society for Paediatric Urology Guidelines on Paediatric Urology: Summary of the 2024 Updates","authors":"Michele Gnech ,&nbsp;Allon van Uitert ,&nbsp;Uchenna Kennedy ,&nbsp;Martin Skott ,&nbsp;Alexandra Zachou ,&nbsp;Berk Burgu ,&nbsp;Marco Castagnetti ,&nbsp;Lisette't Hoen ,&nbsp;Fardod O'Kelly ,&nbsp;Josine Quaedackers ,&nbsp;Yazan F. Rawashdeh ,&nbsp;Mesrur Selcuk Silay ,&nbsp;Guy Bogaert ,&nbsp;Christian Radmayr","doi":"10.1016/j.eururo.2024.03.025","DOIUrl":"10.1016/j.eururo.2024.03.025","url":null,"abstract":"<div><h3>Background and objective</h3><div>We present an overview of the 2024 updates for the European Association of Urology (EAU)/European Society for Paediatric Urology (ESPU) guidelines on paediatric urology to offer evidence-based standards for perioperative management, minimally invasive surgery (MIS), hydrocele, congenital lower urinary tract obstruction (CLUTO), trauma/emergencies, and fertility preservation.</div></div><div><h3>Methods</h3><div>A broad literature search was performed for each condition. Recommendations were developed and rated as strong or weak on the basis of the quality of the evidence, the benefit/harm ratio, and potential patient preferences.</div></div><div><h3>Key findings and limitations</h3><div>Recommendations for perioperative management include points related to fasting, premedication, antibiotic prophylaxis, pain control, and thromboprophylaxis in patients requiring general anaesthesia. MIS use is increasing in paediatric urology, with no major differences observed among different MIS approaches. For hydrocele, observation is the initial approach recommended. For persistent cases, treatment varies according to the type of hydrocele. CLUTO cases should be managed in tertiary centres with multidisciplinary expertise in prenatal and postnatal management. Neonatal valve ablation remains the mainstay of treatment, but associated bladder dysfunction requires continuous treatment. Among urological traumas and emergencies, renal trauma is still an important cause of morbidity and mortality. Conservative management has become the standard approach in haemodynamically stable children. Ischaemic priapism is a medical emergency and requires stepwise management. Initial management of nonischaemic priapism is conservative. Fertility preservation in prepubertal children and adolescents has become an increasingly relevant issue owing to the ever-increasing number of cancer survivors receiving gonadotoxic therapies. A major limitation is the scarcity of relevant literature.</div></div><div><h3>Conclusions and clinical implications</h3><div>This summary of the 2024 EAU/ESPU guidelines provides updated guidance for evidence-based management of some paediatric urological conditions.</div></div><div><h3>Patient summary</h3><div>We provide a summary of the updated European Association of Urology/European Society for Paediatric Urology guidelines on paediatric urology. There are recommendations on steps to take before and immediately after surgery, management of hydrocele, congenital lower urinary tract obstruction, and urological trauma/emergencies, as well as preservation of fertility. Recommendations are based on a comprehensive review of recent studies.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 447-456"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140760279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Best Practice in Using Social Media: The European Association of Urology Position Statement","authors":"Jeremy Yuen-Chun Teoh, Nikita R. Bhatt, Vito Cucchiara, Esther Garcia Rojo, Vineet Gauhar, Claudia Mercader, Benjamin Pradere, Wesley Verla, Julie Darraugh, Carla Bezuidenhout, Marc van Gurp, Elisabeth Hesston, Jarka Bloemberg, James N’Dow, Maria J. Ribal, Gianluca Giannarini","doi":"10.1016/j.eururo.2024.10.018","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.018","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>General principles for SoMe use</h2>There are ten general principles that urologists should follow when using SoMe platforms (Fig. 1) [1]. Physicians should clearly state their role and align their online behavior with professional standards. It is essential to protect patient privacy by avoiding identifiable information and discussing treatment details only with explicit consent. To prevent misinterpretation, medical advice should not be given publicly on SoMe. Instead, patients should be directed to formal consultations or</section></section><section><section><h2>Goals and benefits of SoMe</h2>Optimization of the use of SoMe in urology requires a clear understanding of the goals and benefits [3], [4]. Potential applications of SoMe are diverse, ranging from raising public awareness and providing education about urological diseases and their prevention, to organizing virtual and hybrid conferences to reach a broader audience, facilitating international networking, enhancing and disseminating collaborative research, and sharing resources for professional training and career</section></section><section><section><h2>Measuring SoMe impact</h2>SoMe analytics involves the collection and analysis of data from SoMe platforms to gauge the effectiveness of information dissemination (Fig. 1) [5]. “Impressions” measure how often a post is displayed, “reach” counts how many unique users see a post, and “engagement” tracks total interactions with a post. The Altmetric Attention Score is a newer metric that evaluates the media presence of an article by aggregating mentions across various SoMe platforms and news outlets. These metrics can be</section></section><section><section><h2>Combating misinformation on SoMe</h2>Studies have shown a high prevalence of misinformation in urology content on SoMe platforms such as YouTube and TikTok. A study revealed that 98% of 55 TikTok videos with the hashtag #prostatecancer, despite having 134 944 individual views, were of moderate to poor quality, with 47% containing misinformation and 10.9% showing commercial bias [6]. It is thus crucial to produce and disseminate accurate information via appropriate channels, such as the EAU Patient Information portal and the</section></section><section><section><h2>Future directions</h2>Novel methods of SoMe dissemination should be used, including audiovisual content on TikTok, Instagram, and Snapchat, and remote educational options on Twitch and Caffeine [9]. SoMe interventions are a novel application of SoMe that can enhance health behaviors and patient engagement via platforms such as Facebook and TikTok. Efforts should be made to standardize these interventions to enhance their credibility and effectiveness, while still ensuring a personalized multidisciplinary approach</section></section>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"63 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection","authors":"Karim A. Touijer, Emily A. Vertosick, Daniel D. Sjoberg, Nicole Liso, Sunny Nalavenkata, Barbara Melao, Vincent P. Laudone, Behfar Ehdaie, Brett Carver, James A. Eastham, Peter T. Scardino, Andrew J. Vickers","doi":"10.1016/j.eururo.2024.10.006","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.006","url":null,"abstract":"<h3>Background and objective</h3>Lymph node dissection (LND) has been standard in cancer surgery for more than a century, yet evidence from randomized trials showing a benefit is scarce. We conducted a clinically integrated randomized trial comparing limited versus extended pelvic LND (PLND) during radical prostatectomy and previously reported comparable biochemical recurrence (BCR) rates. We report updated BCR rates and compare rates of metastasis between the study arms.<h3>Methods</h3>Between October 2011 and March 2017, 1432 patients undergoing radical prostatectomy were enrolled at a single center. Surgeons were cluster randomized to perform limited (external iliac nodes) or extended PLND (external iliac, obturator, and hypogastric nodes) with crossover for 3-mo periods. Cox proportional-hazards regression with robust standard errors clustered by surgeon was used to assess whether the PLND template affected BCR or distant or locoregional metastasis.<h3>Key findings and limitations</h3>There were 452 BCR events at median follow-up of 4.2 yr for participants who did not develop BCR. The results confirm our previous finding of comparable BCR rates between the arms (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.97–1.13; <em>p</em> = 0.3). However, with 123 metastasis events and median follow-up of 5.4 yr for patients without metastasis, we found a clinically and statistically significant protective effect of extended PLND against metastasis (any metastasis: HR 0.82, 95% CI 0.71–0.93; <em>p</em> = 0.003; distant metastasis: HR 0.75, 95% CI 0.64–0.88; <em>p</em> &lt; 0.001).<h3>Conclusions and clinical implications</h3>Patients undergoing radical prostatectomy should receive extended PLND that includes the external iliac, obturator, and hypogastric nodes. Further research should examine biological mechanisms regarding the anatomic location of affected nodes. Trials of LND for other cancers are warranted and should consider our clinically integrated design.This trial is registered on ClinicalTrials.gov as NCT01407263.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"15 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142536555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transporting Testosterone Home: Navigating the Road to Recovery","authors":"Vedang Murthy, Alan Dal Pra","doi":"10.1016/j.eururo.2024.10.016","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.016","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"35 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What’s in a Name? Why Words Matter in Advanced Prostate Cancer","authors":"William K. Oh, Neeraj Agarwal, Alan Bryce, Pedro Barata, Courtney Bugler, Sigrid V. Carlsson, Brad Cornell, William Dahut, Daniel George, Stacy Loeb, Bruce Montgomery, David Morris, Lorelei A. Mucci, Aurelius Omlin, Ganesh Palapattu, Irbaz Bin Riaz, Charles Ryan, Martin W. Schoen, Samuel L. Washington, Silke Gillessen","doi":"10.1016/j.eururo.2024.10.017","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.017","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Metastatic hormone-sensitive prostate cancer (mHSPC)</h2>The debate concerning the scientific accuracy and negative connotations of the word “castration” for patients has been discussed previously [3], [4] and is clearly a prominent example of the powers—positive and negative—mentioned above. In particular, we believe that the word “castration” is difficult for patients, partners, and families to hear and should be avoided when we describe this advanced prostate cancer disease state. mHSPC is the most common term for patients with newly diagnosed</section></section><section><section><h2>Androgen deprivation–resistant prostate cancer (ARPC)</h2>One widely used term is “castration-resistant” prostate cancer. Since all patients with this disease state are resistant to androgen deprivation, we propose a new term: androgen deprivation–resistant prostate cancer (ARPC).</section></section><section><section><h2>Androgen receptor pathway inhibitors (ARPI)</h2>The class of androgen receptor (AR) pathway inhibitors (eg, abiraterone acetate, apalutamide, darolutamide, enzalutamide) appears to have many names, going back decades to the first “anti-androgens” such as bicalutamide. Currently, various terms such as AR signaling inhibitors (ARSI), novel hormonal therapies (NHT), AR-targeted agents (ARTA), and second- or next-generation hormonal therapies are all used. Unfortunately, this nomenclature is not only confusing but is also prone to becoming</section></section><section><section><h2>Combination therapy for mHSPC (ADT plus ARPI +/- docetaxel)</h2>Multiple randomized trials have demonstrated superior overall survival in mHSPC with the addition of an ARPI to ADT (“doublet therapy”) or an ARPI to ADT and docetaxel chemotherapy (“triplet therapy”) [6], [7]. Describing regimens comprising two or three drugs as doublets or triplets may be descriptive but can easily be misinterpreted. For instance, the term “triplet therapy” in mHSPC has been used to describe ADT + ARPI + radiation therapy to the prostate by some investigators. Future</section></section>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"34 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and Considerations in Modern Adjuvant Therapy Trials in Renal Cell Carcinoma: A Call to Power","authors":"Daniel D. Shapiro, Pavlos Msaouel","doi":"10.1016/j.eururo.2024.10.020","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.10.020","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"75 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Natural History of Histologically Benign PIRADS 4–5 Lesions in Multiparametric MRI: Real-life Experience in an Academic Center","authors":"Vincenzo Ficarra, Gabriele Sorce, Marta Rossanese, Ettore Di Trapani","doi":"10.1016/j.eururo.2024.09.027","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.09.027","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"21 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142489144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}